Carbon Equity is a platform that enables investors to access carbon markets and invest in carbon credits as an asset class. The company leverages technology to provide a transparent and efficient marketplace for trading carbon credits, with a focus on supporting climate action and sustainable development.

Jeff Gomez

Lara Koole

Tim Molendijk

Jacqueline van den Ende

Carbon Equity

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Ofir Paz

InspireMD, Inc.

GroCapital is an investment firm that focuses on enabling digital transformation and energy sustainability through its portfolio companies, which provide various technological solutions.

GroCapital

Carbon Equity is the world’s first impact investing platform that gives investors small ticket access to leading climate private equity funds. From the global pool of 800+ funds we’ve identified, we select top funds based on climate impact and financial performance. Carbon Equity caters to anyone interested in the intersection of climate and tech, and seeks to move the needle with their money. Carbon Equity is a European venture-backed platform founded by highly experienced investors and tech entrepreneurs.

Metric
Company Name	Carbon Equity	InspireMD, Inc.	GroCapital
Symbol		NSPR
MSH ID	COM:CARBONEQUITY	COM:INSPIREMD	DK:GROCAPITAL
Market	PRIVATE	STOCKS	PRIVATE
Sector	Financial Services & Finance	Healthcare	Technology
Industry	Environmental Finance	Medical - Devices	Investment Management
Country	NL	IL	DK
Stage
Employee Count	41	68
Website	carbonequity.com	inspiremd.com	grocapital.dk
LinkedIn	carbon-equity		gro-capital
Founders

Metric
Market Cap	23.10M	61.65M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		6.21M
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.81M
EBITDA		-20.66M
Operating Income		-20.89M
Net Income		-19.92M
EPS		-0.82
Diluted EPS		-0.82
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.29
Operating Profit Margin		-3.41
EBITDA Margin		-3.33
Net Profit Margin		-2.63
Return on Equity		-0.55
Return on Assets		-0.31
Return on Capital Employed		-0.49

COM:CARBONEQUITY

Carbon Equity

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-4.86
P/B Ratio		2.16
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		13.06
EV Multiple		-2.56

Metric
Days Sales Outstanding		93.95
Days Payables Outstanding		55.16
Days Inventory Outstanding		181.31
Operating Cycle		319.02
Cash Conversion Cycle		241.09
Asset Turnover		0.15

Metric
Operating Cash Flow		-16.38M
Free Cash Flow		-16.76M
Cash Flow to Debt
Operating Cash Flow/Sales		-2.02
Free Cash Flow Yield		-0.26

Metric
Cash & Equivalents		9.64M
Accounts Receivable		-1.21M
Inventory		2.11M
Goodwill
Debt to Capitalization		0.04
Debt to Assets		0.03
Current Ratio		9.96
Quick Ratio		7.41

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.59
R&D to Revenue		1.46
SG&A to Revenue		1.86